Biosensis Pty Ltd

Biosensis, part of the Antibodies Inc. family, specializes in high quality antibodies, ELISA kits, and reagents for neuroscience research. With more than 30 years of expertise, Biosensis is widely recognized as a global leader in neurotrophins and neurotrophin receptor research, serving as a trusted OEM supplier to partners worldwide. The Biosensis portfolio supports research across neurodegenerative disease, neurodevelopment, and neurobiology. Key areas of focus include Alzheimer’s disease, Parkinson’s disease, ALS, neuroimmunology, inflammation, autophagy, and metabolic and stress related disorders. Its reagents are designed to enable accurate detection and analysis of critical biomarkers involved in neuronal function and disease progression. Biosensis offers more than 200 ELISA kits targeting a wide range of proteins. These assays are validated across multiple sample types and are designed as complete, ready to use kits with no need for additional reagents or plates. Flexible strip formats allow efficient use of materials, while detailed protocols support consistent and reproducible results. The Rapid ELISA platform delivers high quality data in less than four hours without compromising sensitivity or specificity. These assays support the detection of key biomarkers such as oligomeric amyloid beta, BDNF, proNGF, and p75NTR, enabling faster insights in areas including neurodegeneration, oncology, and psychiatric research. Backed by an experienced scientific team, Biosensis is committed to providing reliable tools and responsive technical support to researchers in academia, biotechnology, and pharmaceutical organizations worldwide.